Government Bone Doctors Schedule Mystery Meeting About Something
Published Date: 12/12/2025
Notice
Summary
The National Institute of Arthritis and Musculoskeletal and Skin Diseases is holding a virtual meeting on January 27, 2026, to discuss research updates and review grant applications. Anyone interested can watch the open session online, but the grant review part is private to protect sensitive info. This meeting affects researchers and organizations seeking funding and helps decide which projects get support.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Grant applications reviewed in closed session
If you are a researcher or organization applying for NIAMS funding, your grant applications will be reviewed privately on January 27, 2026 from 2:45 p.m. to 3:00 p.m. The session is closed under 5 U.S.C. 552b(c)(4) and (6) to protect confidential trade secrets, patentable material, and personal information.
Open session videocast available
You can watch the open portion of the NIAMS Advisory Council meeting online on January 27, 2026 from 9:30 a.m. to 2:45 p.m. The open session will be videocast at https://videocast.nih.gov/watch=57112 and registration is not required to view it.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-22673, Agency Information Collection Activities: Comment Request; National Science Foundation (NSF) Innovation Corps (I-CorpsTM) Program Pre-submission Executive Summary Form
The National Science Foundation (NSF) is asking for public feedback on a form used by innovators applying to their I-Corps program. This form helps NSF understand new ideas before full proposals are submitted. Comments are open for 30 days, and this process won’t cost anyone money but aims to make the application smoother and clearer.
Next: 2025-22676, Determination That ZANTAC (Ranitidine Hydrochloride) Injection, Equivalent to 25 Milligrams Base/Milliliter, Has Not Been Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that ZANTAC injection (25 mg/mL) hasn’t been pulled from the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they meet safety rules, especially about tiny impurities. Patients and drug makers can breathe easy knowing ZANTAC injection stays available under strict quality checks.